Main Article Content


Infertility is an important problem experienced by a significant proportion of couples in the population. Hyperprolactinemia is a key finding in a subset of women with primary and secondary infertility. Pergoline has been investigated by many authors to reduce serum prolactin and to increase ovarian follicle size; however, significant controversy is present in the available literature to justify conductance of the present study. This study was aimed to evaluate the role of pergoline treatment in a subset of subfertile Iraqi women on both ovarian follicle size and serum prolactin level. The current study involved 60 subfertile women who were treated with pergoline at a dose of 2.5 mg every 3 days for 8 weeks. Baseline estimation of serum prolactin and ovarian follicle size at luteal phase was performed and the second reading of these variables was conducted 8 weeks after treatment. The study was carried out in Al-Diwaniyah maternity and child teaching hospital in Al-Diwaniyah province, Iraq. The study was started at August 2016 and extended through January 2018. The results revealed that after 8 weeks from regular treatment with pergoline, serum prolactin was highly significantly reduced from 64 (45) ng/ml to 30.4 (24) ng/ml (P <0.001). In addition, it was found that the follicle size was highly significantly increased from 10 (2) mm to 17.5 (4.75) mm (P<0.001). It has been concluded that pergoline is an effective mode of treatment to treat subfertile women with asymptomatic hyperprolactinemia and to increase the size of growing ovarian follicles.


Pergoline Ovarian follicles Subfertile women Prolactin

Article Details

How to Cite
Sinaa Abdul Amir Kadhim, Buthainah Abbas Farhan, & Shaimaa Abdul Ameer Kadhum. (2018). Dose specification of Dopamine agonist, pergoline: Treatment in a cohort of subfertile Iraqi women with asymptomatic hyperprolactinemia: A prospec-tive study. International Journal of Research in Pharmaceutical Sciences, 9(2). Retrieved from